Vor Biopharma Inc
NASDAQ:VOR
Income Statement
Earnings Waterfall
Vor Biopharma Inc
Income Statement
Vor Biopharma Inc
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||
| Operating Expenses |
(24)
|
(32)
|
(43)
|
(49)
|
(60)
|
(66)
|
(69)
|
(78)
|
(82)
|
(87)
|
(93)
|
(101)
|
(111)
|
(123)
|
(126)
|
(128)
|
(125)
|
(118)
|
(121)
|
(122)
|
(367)
|
(367)
|
|
| Selling, General & Administrative |
(7)
|
(8)
|
(12)
|
(15)
|
(18)
|
(20)
|
(21)
|
(24)
|
(25)
|
(27)
|
(29)
|
(30)
|
(32)
|
(32)
|
(32)
|
(31)
|
(30)
|
(29)
|
(28)
|
(26)
|
(32)
|
(39)
|
|
| Research & Development |
(17)
|
(23)
|
(32)
|
(34)
|
(41)
|
(46)
|
(48)
|
(54)
|
(56)
|
(60)
|
(65)
|
(71)
|
(80)
|
(90)
|
(94)
|
(97)
|
(95)
|
(89)
|
(93)
|
(96)
|
(335)
|
(328)
|
|
| Operating Income |
(24)
N/A
|
(32)
-34%
|
(43)
-37%
|
(49)
-13%
|
(60)
-21%
|
(66)
-11%
|
(69)
-4%
|
(78)
-13%
|
(82)
-4%
|
(87)
-7%
|
(93)
-7%
|
(101)
-8%
|
(111)
-10%
|
(123)
-10%
|
(126)
-3%
|
(128)
-2%
|
(125)
+2%
|
(118)
+5%
|
(121)
-3%
|
(122)
-1%
|
(367)
-201%
|
(367)
+0%
|
|
| Pre-Tax Income | |||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
5
|
7
|
8
|
8
|
7
|
6
|
4
|
4
|
3
|
4
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 300)
|
(2 086)
|
|
| Pre-Tax Income |
(23)
N/A
|
(32)
-35%
|
(43)
-37%
|
(49)
-14%
|
(60)
-21%
|
(66)
-11%
|
(69)
-4%
|
(78)
-13%
|
(81)
-4%
|
(86)
-6%
|
(92)
-7%
|
(98)
-6%
|
(106)
-9%
|
(116)
-9%
|
(118)
-2%
|
(120)
-2%
|
(118)
+2%
|
(112)
+5%
|
(117)
-4%
|
(119)
-1%
|
(1 664)
-1 303%
|
(2 450)
-47%
|
|
| Net Income | |||||||||||||||||||||||
| Income from Continuing Operations |
(23)
|
(32)
|
(43)
|
(49)
|
(60)
|
(66)
|
(69)
|
(78)
|
(81)
|
(86)
|
(92)
|
(98)
|
(106)
|
(116)
|
(118)
|
(120)
|
(118)
|
(112)
|
(117)
|
(119)
|
(1 664)
|
(2 450)
|
|
| Net Income (Common) |
(26)
N/A
|
(36)
-38%
|
(49)
-37%
|
(56)
-13%
|
(65)
-17%
|
(70)
-7%
|
(70)
-1%
|
(78)
-11%
|
(81)
-4%
|
(86)
-6%
|
(92)
-7%
|
(98)
-6%
|
(106)
-9%
|
(116)
-9%
|
(118)
-2%
|
(120)
-2%
|
(118)
+2%
|
(112)
+5%
|
(117)
-4%
|
(119)
-1%
|
(1 664)
-1 303%
|
(2 450)
-47%
|
|
| EPS (Diluted) |
-14.59
N/A
|
-20.1
-38%
|
-27.63
-37%
|
-30.26
-10%
|
-35.3
-17%
|
-37.74
-7%
|
-41.95
-11%
|
-41.78
+0%
|
-43.37
-4%
|
-45.48
-5%
|
-46.56
-2%
|
-29.51
+37%
|
-31.65
-7%
|
-34.17
-8%
|
-35.08
-3%
|
-35.34
-1%
|
-34.58
+2%
|
-32.85
+5%
|
-34.03
-4%
|
-19
+44%
|
-265.73
-1 299%
|
-366.6
-38%
|
|